A citation-based method for searching scientific literature

Aimee R Hayes, Alexander Crawford, Khulood Al Riyami, Christine Tang, Jamshed Bomanji, Stephanie E Baldeweg, Damian Wild, Daniel Morganstein, Alice Harry, Simona Grozinsky-Glasberg, Kira Oleinikov, Bernard Khoo, Martyn E Caplin, Guillaume P Nicolas, Ashley B Grossman. J Clin Endocrinol Metab 2021
Times Cited: 7







List of co-cited articles
65 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial.
Samuel A Wells, Bruce G Robinson, Robert F Gagel, Henning Dralle, James A Fagin, Massimo Santoro, Eric Baudin, Rossella Elisei, Barbara Jarzab, James R Vasselli,[...]. J Clin Oncol 2012
849
71

Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma.
Samuel A Wells, Sylvia L Asa, Henning Dralle, Rossella Elisei, Douglas B Evans, Robert F Gagel, Nancy Lee, Andreas Machens, Jeffrey F Moley, Furio Pacini,[...]. Thyroid 2015
929
57

Efficacy of Selpercatinib in RET-Altered Thyroid Cancers.
Lori J Wirth, Eric Sherman, Bruce Robinson, Benjamin Solomon, Hyunseok Kang, Jochen Lorch, Francis Worden, Marcia Brose, Jyoti Patel, Sophie Leboulleux,[...]. N Engl J Med 2020
171
57

Cabozantinib in progressive medullary thyroid cancer.
Rossella Elisei, Martin J Schlumberger, Stefan P Müller, Patrick Schöffski, Marcia S Brose, Manisha H Shah, Lisa Licitra, Barbara Jarzab, Viktor Medvedev, Michael C Kreissl,[...]. J Clin Oncol 2013
658
57

Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1/2 study.
Vivek Subbiah, Mimi I Hu, Lori J Wirth, Martin Schuler, Aaron S Mansfield, Giuseppe Curigliano, Marcia S Brose, Viola W Zhu, Sophie Leboulleux, Daniel W Bowles,[...]. Lancet Diabetes Endocrinol 2021
49
42



Overall survival analysis of EXAM, a phase III trial of cabozantinib in patients with radiographically progressive medullary thyroid carcinoma.
M Schlumberger, R Elisei, S Müller, P Schöffski, M Brose, M Shah, L Licitra, J Krajewska, M C Kreissl, B Niederle,[...]. Ann Oncol 2017
81
42

Structural basis of acquired resistance to selpercatinib and pralsetinib mediated by non-gatekeeper RET mutations.
V Subbiah, T Shen, S S Terzyan, X Liu, X Hu, K P Patel, M Hu, M Cabanillas, A Behrang, F Meric-Bernstam,[...]. Ann Oncol 2021
52
42

Lenvatinib versus placebo in radioiodine-refractory thyroid cancer.
Martin Schlumberger, Makoto Tahara, Lori J Wirth, Bruce Robinson, Marcia S Brose, Rossella Elisei, Mouhammed Amir Habra, Kate Newbold, Manisha H Shah, Ana O Hoff,[...]. N Engl J Med 2015
940
42

Response to [90Yttrium-DOTA]-TOC treatment is associated with long-term survival benefit in metastasized medullary thyroid cancer: a phase II clinical trial.
Fabienne Iten, Beat Müller, Christian Schindler, Christoph Rochlitz, Daniel Oertli, Helmut R Mäcke, Jan Müller-Brand, Martin A Walter. Clin Cancer Res 2007
95
42

Selective activation of somatostatin receptor subtypes differentially modulates secretion and viability in human medullary thyroid carcinoma primary cultures: potential clinical perspectives.
Maria Chiara Zatelli, Daniela Piccin, Federico Tagliati, Arianna Bottoni, Andrea Luchin, Cristina Vignali, Angelo Margutti, Marta Bondanelli, Gian Carlo Pansini, Maria Rosa Pelizzo,[...]. J Clin Endocrinol Metab 2006
45
42

Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial.
Marcia S Brose, Christopher M Nutting, Barbara Jarzab, Rossella Elisei, Salvatore Siena, Lars Bastholt, Christelle de la Fouchardiere, Furio Pacini, Ralf Paschke, Young Kee Shong,[...]. Lancet 2014
827
42

Peptide Receptor Radionuclide Therapy (PRRT) of Medullary and Nonmedullary Thyroid Cancer Using Radiolabeled Somatostatin Analogues.
Ali Salavati, Ameya Puranik, Harshad R Kulkarni, Hendra Budiawan, Richard P Baum. Semin Nucl Med 2016
38
42

Anlotinib in Locally Advanced or Metastatic Medullary Thyroid Carcinoma: A Randomized, Double-Blind Phase IIB Trial.
Dapeng Li, Yihebali Chi, Xiaohong Chen, Minghua Ge, Yuan Zhang, Zhuming Guo, Jun Wang, Jie Chen, Jiewu Zhang, Ying Cheng,[...]. Clin Cancer Res 2021
12
28

Preliminary report of the use of everolimus in a patient with progressive medullary thyroid carcinoma.
Maralyn Druce, Teng-Teng Chung, Simona Grozinsky-Glasberg, David J Gross, Ashley B Grossman. Clin Endocrinol (Oxf) 2012
15
28

Medullary thyroid cancer treated with vandetanib: predictors of a longer and durable response.
Laura Valerio, Valeria Bottici, Antonio Matrone, Paolo Piaggi, David Viola, Virginia Cappagli, Laura Agate, Eleonora Molinaro, Raffaele Ciampi, Alessia Tacito,[...]. Endocr Relat Cancer 2020
9
28

The antiproliferative effect of pasireotide LAR alone and in combination with everolimus in patients with medullary thyroid cancer: a single-center, open-label, phase II, proof-of-concept study.
Antongiulio Faggiano, Roberta Modica, Rosa Severino, Luigi Camera, Rosa Fonti, Michela Del Prete, Maria Grazia Chiofalo, Massimo Aria, Piero Ferolla, Giovanni Vitale,[...]. Endocrine 2018
11
28

A multicenter phase 2 trial of pazopanib in metastatic and progressive medullary thyroid carcinoma: MC057H.
Keith C Bible, Vera J Suman, Julian R Molina, Robert C Smallridge, William J Maples, Michael E Menefee, Joseph Rubin, Nina Karlin, Kostandinos Sideras, John C Morris,[...]. J Clin Endocrinol Metab 2014
71
28

EANM practice guideline for PET/CT imaging in medullary thyroid carcinoma.
Luca Giovanella, Giorgio Treglia, Ioannis Iakovou, Jasna Mihailovic, Frederik A Verburg, Markus Luster. Eur J Nucl Med Mol Imaging 2020
35
28

Selective RET kinase inhibition for patients with RET-altered cancers.
V Subbiah, V Velcheti, B B Tuch, K Ebata, N L Busaidy, M E Cabanillas, L J Wirth, S Stock, S Smith, V Lauriault,[...]. Ann Oncol 2018
186
28

Chemotherapy and tyrosine-kinase inhibitors for medullary thyroid cancer.
Julien Hadoux, Martin Schlumberger. Best Pract Res Clin Endocrinol Metab 2017
22
28

Thyroid carcinoma, version 2.2014.
R Michael Tuttle, Robert I Haddad, Douglas W Ball, David Byrd, Paxton Dickson, Quan-Yang Duh, Hormoz Ehya, Megan Haymart, Carl Hoh, Jason P Hunt,[...]. J Natl Compr Canc Netw 2014
109
28

Real-World Efficacy and Safety of Cabozantinib and Vandetanib in Advanced Medullary Thyroid Cancer.
Viktoria F Koehler, Pia Adam, Karin Frank-Raue, Friedhelm Raue, Elke Berg, Eva Hoster, Stephanie Allelein, Matthias Schott, Matthias Kroiss, Christine Spitzweg. Thyroid 2021
17
28

Precision Targeted Therapy with BLU-667 for RET-Driven Cancers.
Vivek Subbiah, Justin F Gainor, Rami Rahal, Jason D Brubaker, Joseph L Kim, Michelle Maynard, Wei Hu, Qiongfang Cao, Michael P Sheets, Douglas Wilson,[...]. Cancer Discov 2018
195
28

Trends in the presentation, treatment, and survival of patients with medullary thyroid cancer over the past 30 years.
Reese W Randle, Courtney J Balentine, Glen E Leverson, Jeffrey A Havlena, Rebecca S Sippel, David F Schneider, Susan C Pitt. Surgery 2017
88
28

Vandetanib in children and adolescents with multiple endocrine neoplasia type 2B associated medullary thyroid carcinoma.
Elizabeth Fox, Brigitte C Widemann, Meredith K Chuk, Leigh Marcus, Alberta Aikin, Patricia O Whitcomb, Maria J Merino, Maya Lodish, Eva Dombi, Seth M Steinberg,[...]. Clin Cancer Res 2013
94
28

Somatic mutations in the RET proto-oncogene in sporadic medullary thyroid carcinomas.
S Dvorakova, E Vaclavikova, V Sykorova, J Vcelak, Z Novak, J Duskova, A Ryska, J Laco, J Cap, D Kodetova,[...]. Mol Cell Endocrinol 2008
69
28

Correlative analyses of RET and RAS mutations in a phase 3 trial of cabozantinib in patients with progressive, metastatic medullary thyroid cancer.
Steven I Sherman, Douglas O Clary, Rossella Elisei, Martin J Schlumberger, Ezra E W Cohen, Patrick Schöffski, Lori J Wirth, Milan Mangeshkar, Dana T Aftab, Marcia S Brose. Cancer 2016
52
28

Management of tyrosine kinase inhibitors (TKI) side effects in differentiated and medullary thyroid cancer patients.
C Resteghini, S Cavalieri, D Galbiati, R Granata, S Alfieri, C Bergamini, P Bossi, L Licitra, L D Locati. Best Pract Res Clin Endocrinol Metab 2017
46
28

A Phase II Trial of the Multitargeted Tyrosine Kinase Inhibitor Lenvatinib (E7080) in Advanced Medullary Thyroid Cancer.
Martin Schlumberger, Barbara Jarzab, Maria E Cabanillas, Bruce Robinson, Furio Pacini, Douglas W Ball, Judith McCaffrey, Kate Newbold, Roger Allison, Renato G Martins,[...]. Clin Cancer Res 2016
134
28

A phase II trial of imatinib therapy for metastatic medullary thyroid carcinoma.
J W B de Groot, B A Zonnenberg, P Quarles van Ufford-Mannesse, M M de Vries, T P Links, C J M Lips, E E Voest. J Clin Endocrinol Metab 2007
129
28

REToma: a cancer subtype with a shared driver oncogene.
Takashi Kohno, Junya Tabata, Takashi Nakaoku. Carcinogenesis 2020
21
28

ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration.
Stephen R Wedge, Donald J Ogilvie, Michael Dukes, Jane Kendrew, Rosemary Chester, Janet A Jackson, Sarah J Boffey, Paula J Valentine, Jon O Curwen, Helen L Musgrove,[...]. Cancer Res 2002
721
28

Radiopeptide transmitted internal irradiation of non-iodophil thyroid cancer and conventionally untreatable medullary thyroid cancer using.
C Waldherr, T Schumacher, M Pless, A Crazzolara, H R Maecke, E U Nitzsche, A Haldemann, J Mueller-Brand. Nucl Med Commun 2001
60
28

Anlotinib for the Treatment of Patients with Locally Advanced or Metastatic Medullary Thyroid Cancer.
Yongkun Sun, Feng Du, Ming Gao, Qinghai Ji, Zhendong Li, Yuan Zhang, Zhuming Guo, Jun Wang, Xiangjin Chen, Jinwan Wang,[...]. Thyroid 2018
61
28

Beneficial Effects of the mTOR Inhibitor Everolimus in Patients with Advanced Medullary Thyroid Carcinoma: Subgroup Results of a Phase II Trial.
T C Schneider, D de Wit, T P Links, N P van Erp, J J M van der Hoeven, H Gelderblom, T van Wezel, R van Eijk, H Morreau, H J Guchelaar,[...]. Int J Endocrinol 2015
34
28

Medullary thyroid carcinoma beyond surgery: advances, challenges, and perspectives.
Lucieli Ceolin, Marta Amaro da Silveira Duval, Antônio Felippe Benini, Carla Vaz Ferreira, Ana Luiza Maia. Endocr Relat Cancer 2019
40
28

Anlotinib: a novel multi-targeting tyrosine kinase inhibitor in clinical development.
Guoshuang Shen, Fangchao Zheng, Dengfeng Ren, Feng Du, Qiuxia Dong, Ziyi Wang, Fuxing Zhao, Raees Ahmad, Jiuda Zhao. J Hematol Oncol 2018
170
28

Receptor radionuclide therapy with 90Y-DOTATOC in patients with medullary thyroid carcinomas.
Lisa Bodei, Daria Handkiewicz-Junak, Chiara Grana, Chiara Mazzetta, Paola Rocca, Mirco Bartolomei, Maribel Lopera Sierra, Marta Cremonesi, Marco Chinol, Helmut R Mäcke,[...]. Cancer Biother Radiopharm 2004
64
28

Risk Factors Associated With Reoperation and Disease-Specific Mortality in Patients With Medullary Thyroid Carcinoma.
Eric J Kuo, Shonan Sho, Ning Li, Kyle A Zanocco, Michael W Yeh, Masha J Livhits. JAMA Surg 2018
33
28

Phase II study of safety and efficacy of motesanib in patients with progressive or symptomatic, advanced or metastatic medullary thyroid cancer.
Martin J Schlumberger, Rossella Elisei, Lars Bastholt, Lori J Wirth, Renato G Martins, Laura D Locati, Barbara Jarzab, Furio Pacini, Chantal Daumerie, Jean-Pierre Droz,[...]. J Clin Oncol 2009
257
28

Cell signaling by receptor tyrosine kinases.
Mark A Lemmon, Joseph Schlessinger. Cell 2010
28

Long-Term Control of Hypercortisolism by Vandetanib in a Case of Medullary Thyroid Carcinoma with a Somatic RET Mutation.
Anne-Cécile Paepegaey, Béatrix Cochand-Priollet, Estelle Louiset, Pierre-Olivier Sarfati, Marco Alifano, Nelly Burnichon, Marie Bienvenu-Perrard, Najiba Lahlou, Léopoldine Bricaire, Lionel Groussin. Thyroid 2017
9
28

The rapamycin-derivative RAD001 (everolimus) inhibits cell viability and interacts with the Akt-mTOR-p70S6K pathway in human medullary thyroid carcinoma cells.
Simona Grozinsky-Glasberg, Hadara Rubinfeld, Yardena Nordenberg, Alexander Gorshtein, Michal Praiss, Efrat Kendler, Rafael Feinmesser, Ashley B Grossman, Ilan Shimon. Mol Cell Endocrinol 2010
31
28

RET Solvent Front Mutations Mediate Acquired Resistance to Selective RET Inhibition in RET-Driven Malignancies.
Benjamin J Solomon, Lavinia Tan, Jessica J Lin, Stephen Q Wong, Sebastian Hollizeck, Kevin Ebata, Brian B Tuch, Satoshi Yoda, Justin F Gainor, Lecia V Sequist,[...]. J Thorac Oncol 2020
89
28

Long-term follow-up and safety of vandetanib for advanced medullary thyroid cancer.
Helton Estrela Ramos, Fabio Hecht, Amandine Berdelou, Isabelle Borget, Sophie Leboulleux, Eric Baudin, Martin Schlumberger. Endocrine 2021
8
28

Trends in Thyroid Cancer Incidence and Mortality in the United States, 1974-2013.
Hyeyeun Lim, Susan S Devesa, Julie A Sosa, David Check, Cari M Kitahara. JAMA 2017
891
28

Mechanisms of resistance to selective RET tyrosine kinase inhibitors in RET fusion-positive non-small-cell lung cancer.
J J Lin, S V Liu, C E McCoach, V W Zhu, A C Tan, S Yoda, J Peterson, A Do, K Prutisto-Chang, I Dagogo-Jack,[...]. Ann Oncol 2020
58
28

A Case Report of Sequential Use of a Yeast-CEA Therapeutic Cancer Vaccine and Anti-PD-L1 Inhibitor in Metastatic Medullary Thyroid Cancer.
Jaydira Del Rivero, Renee N Donahue, Jennifer L Marté, Ann W Gramza, Marijo Bilusic, Myrna Rauckhorst, Lisa Cordes, Maria J Merino, William L Dahut, Jeffrey Schlom,[...]. Front Endocrinol (Lausanne) 2020
5
40


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.